ProKidney Virtual KOL Event to Discuss Current Treatment Landscape in Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial of Renal Autologous Cell Therapy (REACT®)
| DATE: | May 28, 2024 |
|---|---|
| TIME: | 8:00 AM EDT |
| LOCATION: | Virtual |
About The Event
Join ProKidney for a virtual KOL event featuring Steven G. Coca, DO, MS (Icahn School of Medicine at Mount Sinai) and Arnold L. Silva, MD, PhD (University of Arizona) who will discuss the unmet medical need and current treatment landscape for patients with moderate to severe chronic kidney disease (CKD) caused by diabetes as well as the importance of preserving kidney function in this patient population.
The event will also focus on reviewing RMCL-002 data from the Phase 2 trial of ProKidney’s lead product candidate, rilparencel (also known as REACT®), a first-of-its-kind, patented, proprietary autologous cellular therapy.
A live question and answer session will follow the formal presentations.